{"id":"atra-chemo","safety":{"commonSideEffects":[{"rate":"5-27","effect":"Differentiation syndrome (APL syndrome)"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Hypertriglyceridemia"},{"rate":null,"effect":"Chemotherapy-related toxicity (nausea, infection, bleeding)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATRA binds to retinoic acid receptors and promotes terminal differentiation of abnormal promyelocytes, converting them from a proliferative to a non-proliferative state. When combined with chemotherapy agents, this differentiation therapy synergizes with cytotoxic chemotherapy to achieve high remission rates. This combination approach has become the standard of care for acute promyelocytic leukemia (APL), particularly in t(15;17) PML-RARA positive disease.","oneSentence":"ATRA (all-trans retinoic acid) combined with chemotherapy induces differentiation of leukemic blasts and enhances chemotherapy cytotoxicity in acute promyelocytic leukemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:30.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL), t(15;17) positive"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT05384821","phase":"PHASE1, PHASE2","title":"Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2022-09-14","conditions":"Wilms Tumor","enrollment":28},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT05345002","phase":"PHASE2","title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","status":"RECRUITING","sponsor":"Stephen Bagley, MD, MSCE","startDate":"2022-11-16","conditions":"Glioma, IDH Mutation, Astrocytoma","enrollment":55},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT07355855","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01","conditions":"Rhabdomyosarcoma","enrollment":106},{"nctId":"NCT07348107","phase":"PHASE1","title":"ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Daniel Breadner","startDate":"2026-02-15","conditions":"Advanced Pancreatic Ductal Adenocarcinoma","enrollment":10},{"nctId":"NCT06706401","phase":"PHASE3","title":"Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-02-20","conditions":"Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer","enrollment":460},{"nctId":"NCT06731140","phase":"PHASE2","title":"Reverse HER2-negative Immune Resistant Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-12","conditions":"HER2 Negative Breast Cancer","enrollment":10},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT00392327","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-05-23","conditions":"Anaplastic Medulloblastoma, Medulloblastoma","enrollment":379},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT06982274","phase":"PHASE2","title":"Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-10-20","conditions":"Acute Promyelocytic Leukemia (APL)","enrollment":115},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT06841952","phase":"NA","title":"Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-02-15","conditions":"AML, Adult","enrollment":158},{"nctId":"NCT06636981","phase":"PHASE2","title":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-04","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":129},{"nctId":"NCT02807558","phase":"PHASE2","title":"A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Syros Pharmaceuticals","startDate":"2016-09-20","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":155},{"nctId":"NCT06703047","phase":"PHASE2","title":"Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT06646666","phase":"PHASE2","title":"ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-01","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":35},{"nctId":"NCT02942758","phase":"PHASE2","title":"Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML","status":"TERMINATED","sponsor":"University Hospital Regensburg","startDate":"2017-04-10","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT01526603","phase":"NA","title":"High Dose Chemotherapy and Autologous Transplant for Neuroblastoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-03-28","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT01728155","phase":"PHASE3","title":"European Low and Intermediate Risk Neuroblastoma Protocol","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2011-01-01","conditions":"LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES","enrollment":685},{"nctId":"NCT00005847","phase":"PHASE2","title":"Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2001-04-05","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00893399","phase":"PHASE3","title":"Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2010-05-12","conditions":"Acute Myeloid Leukemia","enrollment":600},{"nctId":"NCT00492856","phase":"PHASE3","title":"S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2007-06-01","conditions":"Leukemia","enrollment":105},{"nctId":"NCT00551460","phase":"PHASE2","title":"S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2007-11-15","conditions":"Leukemia","enrollment":78},{"nctId":"NCT05497310","phase":"PHASE1, PHASE2","title":"Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL","status":"UNKNOWN","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2022-07-01","conditions":"Promyelocytic Leukemia","enrollment":15},{"nctId":"NCT00866918","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-03-09","conditions":"Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm","enrollment":106},{"nctId":"NCT00482833","phase":"PHASE3","title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-08","conditions":"Leukemia","enrollment":276},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT02200978","phase":"PHASE4","title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","status":"COMPLETED","sponsor":"South China Children's Leukemia Group","startDate":"2011-09","conditions":"Childhood Acute Promyelocytic Leukemia","enrollment":176},{"nctId":"NCT00867178","phase":"PHASE1","title":"Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-02-25","conditions":"Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":33},{"nctId":"NCT01404949","phase":"PHASE2","title":"Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-07","conditions":"Acute Promyelocytic Leukemia","enrollment":17},{"nctId":"NCT00003405","phase":"PHASE2","title":"Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"1998-04","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00528437","phase":"PHASE2","title":"Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2005-10","conditions":"Brain Tumors","enrollment":46},{"nctId":"NCT00499616","phase":"PHASE3","title":"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-08","conditions":"Neuroblastoma","enrollment":464},{"nctId":"NCT04433169","phase":"PHASE2","title":"All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck","status":"UNKNOWN","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2020-06-03","conditions":"Adenoid Cystic Carcinoma of the Head and Neck","enrollment":30},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00617409","phase":"PHASE2","title":"To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-10-02","conditions":"Small Cell Lung Cancer","enrollment":69},{"nctId":"NCT01987297","phase":"PHASE4","title":"Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-06","conditions":"Acute Promyelocytic Leukemia","enrollment":738},{"nctId":"NCT03259516","phase":"PHASE1, PHASE2","title":"Nivolumab With Chemotherapy in Refractory MDS","status":"TERMINATED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2017-05-25","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT00793845","phase":"PHASE2","title":"Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-08","conditions":"Neuroblastoma","enrollment":40},{"nctId":"NCT03061656","phase":"PHASE2","title":"Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"High Risk Neuroblastoma","enrollment":40},{"nctId":"NCT00439673","phase":"PHASE2","title":"PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-05","conditions":"Myelodysplastic Syndromes","enrollment":62},{"nctId":"NCT01237808","phase":"PHASE3","title":"Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2011-03","conditions":"Acute Myeloid Leukemia (AML)","enrollment":144},{"nctId":"NCT01276730","phase":"PHASE2","title":"Advanced Cervical Cancer Trial in India","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2007-10","conditions":"Cervical Cancer","enrollment":209},{"nctId":"NCT00808899","phase":"PHASE2","title":"Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-12","conditions":"Neuroblastoma","enrollment":4},{"nctId":"NCT01820624","phase":"PHASE1","title":"Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Paolo Caimi, MD","startDate":"2013-04-30","conditions":"Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)","enrollment":12},{"nctId":"NCT03042429","phase":"PHASE3","title":"Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2007-01-01","conditions":"Neuroblastoma","enrollment":360},{"nctId":"NCT00867672","phase":"PHASE2","title":"Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2011-08","conditions":"Acute Myeloid Leukemia","enrollment":204},{"nctId":"NCT02845232","phase":"","title":"Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-03","conditions":"Acute Myeloid Leukemia","enrollment":214},{"nctId":"NCT01067274","phase":"PHASE3","title":"ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)","status":"WITHDRAWN","sponsor":"Acute Leukemia French Association","startDate":"2010-04","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT01369368","phase":"PHASE1, PHASE2","title":"Treatment of Acute Leukemia Relapse After Allotransplantation","status":"UNKNOWN","sponsor":"University of Bergen","startDate":"2013-08","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT00078988","phase":"PHASE3","title":"High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-10","conditions":"Brain Tumor, Central Nervous System Tumor","enrollment":1},{"nctId":"NCT00408278","phase":"PHASE4","title":"Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2005-07","conditions":"Acute Promyelocytic Leukemia","enrollment":300},{"nctId":"NCT01349556","phase":"NA","title":"Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2011-05","conditions":"Medication Reaction","enrollment":""},{"nctId":"NCT00276601","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2004-10","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00514293","phase":"PHASE2","title":"Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Raghu Nandan, M.D., Inc","startDate":"2007-01","conditions":"Lung Cancer","enrollment":39},{"nctId":"NCT00002658","phase":"PHASE3","title":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"1994-01","conditions":"Leukemia, Neutropenia","enrollment":2000},{"nctId":"NCT00005863","phase":"PHASE3","title":"Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"1998-08","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":""},{"nctId":"NCT00005823","phase":"PHASE3","title":"Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Leukemia Research Fund","startDate":"1998-12","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":2000},{"nctId":"NCT00005825","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Raghu Nandan, M.D., Inc","startDate":"1998-09","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00002701","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1995-10","conditions":"Leukemia","enrollment":750},{"nctId":"NCT00017225","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"1997-05","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00003619","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"1998-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT00003934","phase":"PHASE3","title":"Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-06","conditions":"Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Childhood Acute Promyelocytic Leukemia (M3)","enrollment":420},{"nctId":"NCT00004188","phase":"PHASE3","title":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2001-02","conditions":"Neuroblastoma","enrollment":495},{"nctId":"NCT00025038","phase":"PHASE2","title":"Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Juvenile Myelomonocytic Leukemia","enrollment":100},{"nctId":"NCT00016159","phase":"PHASE2","title":"Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-11","conditions":"Leukemia","enrollment":35},{"nctId":"NCT00002737","phase":"PHASE3","title":"Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1996-03","conditions":"Kidney Cancer","enrollment":320},{"nctId":"NCT00326170","phase":"PHASE2","title":"Phase II 5-Azacytidine Plus VPA Plus ATRA","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-07","conditions":"Myelodysplastic Syndrome, Acute Myelogenous Leukemia","enrollment":34},{"nctId":"NCT00005969","phase":"PHASE2","title":"Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"1999-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01048645","phase":"PHASE2","title":"Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2007-09","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":107},{"nctId":"NCT01041833","phase":"PHASE3","title":"Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker","status":"UNKNOWN","sponsor":"National Institute of Cancerología","startDate":"2010-01","conditions":"Non Small Cell Lung Cancer","enrollment":230},{"nctId":"NCT00962767","phase":"PHASE3","title":"Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-05","conditions":"Leukemia, Myelocytic, Acute","enrollment":168},{"nctId":"NCT00599937","phase":"PHASE3","title":"APL93: Timing of CxT and Role of Maintenance","status":"COMPLETED","sponsor":"Groupe d'etude et de travail sur les leucemies aigues promyelocytaires","startDate":"1993-01","conditions":"Leukemia, Promyelocytic, Acute","enrollment":576},{"nctId":"NCT00591526","phase":"PHASE3","title":"A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)","status":"COMPLETED","sponsor":"Groupe d'etude et de travail sur les leucemies aigues promyelocytaires","startDate":"2000-06","conditions":"Leukemia, Promyelocytic, Acute","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["retinoic acid + idarubicin or daunorubicin +/- Cytarabine"],"phase":"marketed","status":"active","brandName":"ATRA+Chemo","genericName":"ATRA+Chemo","companyName":"Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATRA (all-trans retinoic acid) combined with chemotherapy induces differentiation of leukemic blasts and enhances chemotherapy cytotoxicity in acute promyelocytic leukemia. Used for Acute promyelocytic leukemia (APL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}